EZH1/2 alteration as a potential biomarker for immune checkpoint inhibitors across multiple cancer types.
- Resource Type
- Article
- Authors
- Huang, Huageng; Deng, Xinyi; Yu, Le; Huang, He; Wang, Zhao; Hong, Huangming; Lin, Tongyu
- Source
- Journal of Translational Medicine. 12/15/2023, Vol. 21 Issue 1, p1-5. 5p.
- Subject
- *IMMUNE checkpoint inhibitors
*BIOMARKERS
*IPILIMUMAB
*MEDICAL screening
- Language
- ISSN
- 1479-5876
This article discusses the potential use of EZH1/2 alteration as a biomarker for immune checkpoint inhibitors (ICIs) in multiple types of cancer. The authors conducted a comprehensive analysis of large datasets and found that EZH1/2 alteration was prevalent in various cancer types and could predict positive outcomes with ICI therapy. The study suggests that screening for EZH1/2 alteration before ICI therapy could help identify patients who are likely to benefit from treatment. However, further research is needed to explore the molecular mechanisms and conduct prospective studies. [Extracted from the article]